BCL2 and acute myeloid leukemia: Many of the biological therapies used to treat AML are inhibitory and block the aberrant gene product, cell cycle/proliferation and epigenetic regulators implicated in AML, such as the Fms‐related receptor tyrosine kinase 3 (FLT3) inhibitor, Rydapt or the Bcl‐2 inhibitor, venetoclax [5, 6].